

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste®

Brighter AB (publ) announced today that its solution for diabetes management – the Actiste®, has been evaluated and proved to be compatible with insulin cartridges from BIOTON S.A. (SciGen Pte. Ltd. – the exclusive distributor of BIOTON products, excluding Poland) with GENSULIN® GENSULIN® N (Scilin®N), GENSULIN® R (Scilin®R), and GENSULIN® M30(Scilin®M30). Currently, Actiste® is intended for use only with insulin cartridges from Sanofi. This has been a limiting factor to Brighter's potential market reach, because Sanofi cartridges are not available in all markets.

“This is a great strategic move and a huge milestone for Brighter. It will open up additional markets with new revenue opportunities worldwide where Bioton / Scigen insulin is available. After finalizing the internal development work, we expect that Actiste® will be marketable for use with the additional insulin and ready for end users already in the second half of the year, says Christer Trägårdh, acting CEO of Brighter.

BIOTON S.A. is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world's top eight commercial manufacturers of recombinant human insulin.

SciGen Pte. Ltd. is a high growth biopharmaceutical company that focuses on recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology and oncology. The company's portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin and rhuman GCSF. All of SciGen's products have undergone substantial clinical development

For more information, please contact:

Investor Relations
ir@brighter.se

Certified Adviser

Brighter's Certified Adviser is Eminova Fondkommission AB, +46 [0]8 - 684 211 10, adviser@eminova.se, www.eminova.se.

About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.





This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 15:45 CET on June 7, 2021



Brighter AB (publ)

Borgarfjordsgatan 18
SE-164 40 Kista
Sweden

+46 (0)8 550 088 20
info@brighter.se
www.brighter.se